Biotron Limited (ASX:BIT)

Market Cap	3.32M
Revenue (ttm)	1.81M
Net Income (ttm)	-1.42M
Shares Out	1.33B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	330,026
Average Volume	617,512
Open	0.0030
Previous Close	0.0020
Day's Range	0.0020 - 0.0030
52-Week Range	0.0020 - 0.0578
Beta	-0.70
RSI	39.85
Earnings Date	May 29, 2025

About Biotron

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BIT

Financial Performance

In 2024, Biotron's revenue was 1.65 million, an increase of 14.94% compared to the previous year's 1.43 million. Losses were -3.44 million, -1.61% less than in 2023.